Baudax Bio Inc (BXRXQ)
OTCMKTS: BXRXQ · Delayed Price · USD
0.0100
0.00 (0.00%)
May 1, 2024, 12:00 AM EDT - Market open
Baudax Bio Revenue
Baudax Bio had revenue of $310.00K in the twelve months ending September 30, 2023, down -22.50% year-over-year. In the year 2022, Baudax Bio had annual revenue of $1.27M with 17.50% growth.
Revenue (ttm)
$310.00K
Revenue Growth
-22.50%
P/S Ratio
0.26
Revenue / Employee
$34,444
Employees
9
Market Cap
79.94K USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 1.27M | 189.00K | 17.50% |
Dec 31, 2021 | 1.08M | 587.00K | 119.07% |
Dec 31, 2020 | 493.00K | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
BXRXQ News
- 7 months ago - Baudax Bio Announces Corporate Update - GlobeNewsWire
- 7 months ago - Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors - GlobeNewsWire
- 8 months ago - Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference - GlobeNewsWire
- 9 months ago - Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock - GlobeNewsWire
- 9 months ago - Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - GlobeNewsWire
- 9 months ago - Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update - GlobeNewsWire
- 10 months ago - Baudax Bio shares jump on acquisition of TeraImmune - Market Watch
- 10 months ago - Baudax Bio Acquires TeraImmune, Inc. - GlobeNewsWire